Efficacy and Safety of Roflumilast Cream 0.15% in Adults and Children Aged ≥6 Years With Mild to Moderate Atopic Dermatitis in Two Phase 3 Trials (INTEGUMENT-1 and INTEGUMENT-2)

Main Article Content

Eric Simpson
Lawrence Eichenfield
Melinda Gooderham
Mercedes E. Gonzalez
Adelaide Hebert
Kim Papp
Vimal H. Prajapati
David Krupa
Patrick Burnett
David Berk
Robert Higham


Atopic Dermatitis, roflumilast, phosphodiesterase 4 inhibitor


1. Gooderham MJ, et al. J Drugs Dermatol. 2023;22:139–147.

2. Berk DR, Osborne DW. Society for Investigative Dermatology Annual Meeting, Portland, OR, USA, 2022.

3. Dong C, et al. J Pharmacol Exp Ther. 2016;358:413–422.

4. Schafer PH, et al. Cell Signal. 2014;26:2016–2029.

Most read articles by the same author(s)

<< < 5 6 7 8 9 10 11 12 > >>